BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 19815485)

  • 1. The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels.
    Aggarwal R; Weinberg V; Small EJ; Oh W; Rushakoff R; Ryan CJ
    Clin Genitourin Cancer; 2009 Oct; 7(3):E71-6. PubMed ID: 19815485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer.
    Oh WK; Kantoff PW; Weinberg V; Jones G; Rini BI; Derynck MK; Bok R; Smith MR; Bubley GJ; Rosen RT; DiPaola RS; Small EJ
    J Clin Oncol; 2004 Sep; 22(18):3705-12. PubMed ID: 15289492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen.
    Narimoto K; Mizokami A; Izumi K; Mihara S; Sawada K; Sugata T; Shimamura M; Miyazaki K; Nishino A; Namiki M
    Int J Urol; 2010 Apr; 17(4):337-45. PubMed ID: 20202011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diethylstilbestrol for the treatment of patients with castration-resistant prostate cancer: retrospective analysis of a single institution experience.
    Grenader T; Plotkin Y; Gips M; Cherny N; Gabizon A
    Oncol Rep; 2014 Jan; 31(1):428-34. PubMed ID: 24247716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene profiling and promoter reporter assays: novel tools for comparing the biological effects of botanical extracts on human prostate cancer cells and understanding their mechanisms of action.
    Bigler D; Gulding KM; Dann R; Sheabar FZ; Conaway MR; Theodorescu D
    Oncogene; 2003 Feb; 22(8):1261-72. PubMed ID: 12606954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer.
    Small EJ; Frohlich MW; Bok R; Shinohara K; Grossfeld G; Rozenblat Z; Kelly WK; Corry M; Reese DM
    J Clin Oncol; 2000 Nov; 18(21):3595-603. PubMed ID: 11054432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.
    Stomati M; Monteleone P; Casarosa E; Quirici B; Puccetti S; Bernardi F; Genazzani AD; Rovati L; Luisi M; Genazzani AR
    Gynecol Endocrinol; 2000 Oct; 14(5):342-63. PubMed ID: 11109974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu.
    Takizawa I; Nishiyama T; Hara N; Isahaya E; Hoshii T; Takahashi K
    Prostate; 2010 Sep; 70(13):1395-401. PubMed ID: 20687212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
    Ryan CJ; Harzstark AH; Rosenberg J; Lin A; Claros C; Goldfine ID; Kerner JF; Small EJ; Youngren JF
    BJU Int; 2008 Feb; 101(4):436-9. PubMed ID: 18234062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
    Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
    Arnold JT; Le H; McFann KK; Blackman MR
    Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.
    Samojlik E; Veldhuis JD; Wells SA; Santen RJ
    J Clin Invest; 1980 Mar; 65(3):602-12. PubMed ID: 6986409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of action of herbal supplement PC-SPES: elucidation of effects of individual herbs of PC-SPES on proliferation and prostate specific gene expression in androgen-dependent LNCaP cells.
    Hsieh TC; Wu JM
    Int J Oncol; 2002 Mar; 20(3):583-8. PubMed ID: 11836572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormonal therapy of prostate cancer.
    Labrie F
    Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PC-SPES: a herbal therapy for the treatment of hormone refractory prostate cancer.
    Meyer JP; Gillatt DA
    Prostate Cancer Prostatic Dis; 2002; 5(1):13-5. PubMed ID: 15195124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients.
    Geisler J; Haynes B; Anker G; Helle H; Ekse D; Dowsett M; Lønning PE
    J Steroid Biochem Mol Biol; 2005 Sep; 96(5):415-22. PubMed ID: 16168635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of intravenous administration of high dose-diethylstilbestrol diphosphate on serum hormonal levels in patients with hormone-refractory prostate cancer.
    Kitahara S; Umeda H; Yano M; Koga F; Sumi S; Moriguchi H; Hosoya Y; Honda M; Yoshida K
    Endocr J; 1999 Oct; 46(5):659-64. PubMed ID: 10670751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer.
    Geller J
    Semin Oncol; 1985 Mar; 12(1 Suppl 1):28-35. PubMed ID: 3883502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma.
    Hellerstedt B; Pienta KJ; Redman BG; Esper P; Dunn R; Fardig J; Olson K; Smith DC
    Cancer; 2003 Oct; 98(8):1603-10. PubMed ID: 14534875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current role of diethylstilbestrol in the management of advanced prostate cancer.
    Bosset PO; Albiges L; Seisen T; de la Motte Rouge T; Phé V; Bitker MO; Rouprêt M
    BJU Int; 2012 Dec; 110(11 Pt C):E826-9. PubMed ID: 22578092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.